Decheng Capital Seeks $700 Million for Fifth Life Sciences Fund Amidst VC Surge

1. Target Raise: Decheng Capital aims to raise $700 million for its fifth life sciences fund.
2. Investment Focus: The firm supports early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence.
3. Portfolio Companies: Decheng's portfolio includes Acelyrin, Arcus Biosciences, CG Oncology, and others that have gone public or been acquired by major pharma players.
4. Recent Deals: Decheng-backed companies have recently signed significant deals, such as Mammoth Biosciences with Regeneron and Cellares with Bristol Myers Squibb.
5. Industry Context: Decheng's announcement follows recent fund closures by Foresite Capital ($900 million) and J.P. Morgan Private Capital ($500 million).